Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction With Statins, Ezetimibe, and PCSK9 Inhibition

IMPORTANCE: Low-density lipoprotein cholesterol (LDL-C) is an important modifiable risk factor for atherosclerotic cardiovascular disease. It is unclear whether the percentage LDL-C lowering with pharmacotherapies differs on the basis of baseline LDL-C levels. OBJECTIVE: To evaluate the association...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :JAMA Cardiol
Главные авторы: Marcusa, Daniel P., Giugliano, Robert P., Park, Jeong-Gun, de Lemos, James A., Cannon, Christopher P., Sabatine, Marc S.
Формат: Artigo
Язык:Inglês
Опубликовано: American Medical Association 2020
Предметы:
Brief Report
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7666429/
https://ncbi.nlm.nih.gov/pubmed/33185670
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2020.6184
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы